A Phase II Randomized Controlled Trial of Renshen Yangrong Tang Herbal Extract Granules for Fatigue Reduction in Cancer Survivors.
Based on the traditional Chinese medicine (TCM) theory, Renshen Yangrong Tang (RSYRT), which mixed with 12 herbs, commonly used as a pharmacological option in China for fatigue management by correcting Qi deficiency. This randomized controlled phase II trial investigated the efficacy of RSYRT for reducing cancer-related fatigue. Cancer survivors with moderate or severe fatigue (rated ≥4 on a 0-10 scale) over 2 months were randomized to take herbal extract granules of RSYRT or a low dose of a single herb (huangqi) twice a day for 6 weeks. Patient-reported fatigue was measured using the MD Anderson Symptom Inventory (MDASI). Efficacy of RSYRT was evaluated using mixed model to test the differences over time among groups. We also conducted responder analyses and examined time to effect of symptom reduction. None of the 83 evaluable patients (control group, 42; intervention group, 41) had discomfort or grade 3 or 4 toxicity. We observed a significantly greater MDASI-fatigue score reduction in the intervention group than in the control group (time-by-group interaction, estimate (est) =-0.61(0.10), P<.0001). More patients in the intervention group had a 2-points reduction on fatigue than the control group (90.2% vs. 52.4%). By week 4, between groups difference of fatigue reduction on mean severity reached large effect size (intervention group vs. control group: -2.66 vs. -1.36, Cohen's d=1.0, P<0.0001). Compared with control therapy, RSYRT therapy elicits a statistical and clinical improvement of fatigue severity and functioning. RSYRT's effectiveness in managing cancer-related fatigue warrant further study in the real world.